RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog

By
A A A

RegeneRx Biopharmaceuticals, Inc. ( RGRX ) and its Hong Kong-based partner Lee's Pharmaceutical Holdings Ltd. announced that the Chinese regulatory authority has accepted a phase II investigational new drug (IND) application for their ophthalmic candidate, RGN-259. RegeneRx and Lee's Pharma expect to initiate a phase II study in the first quarter of 2015.

RGN-259 is a thymosin beta 4-based, preservative-free eye drop. The companies plan to evaluate the candidate in patients suffering from moderate-to-severe dry eye syndrome in China.

We remind investors that RegeneRx had entered into a licensing agreement with Lee's Pharma in Jul 2012 for several pipeline candidates including RGN-259 in China, Hong Kong, Macau and Taiwan.

Previous Studies on RGN-259

In Jun 2012, RegeneRx reported preliminary results from a double-masked, vehicle-controlled, physician-sponsored phase II study on RGN-259 for the treatment of severe dry eye. The study met its key efficacy objectives with statistically significant sign and symptom improvements observed in the RGN-259 arm as compared to the vehicle control arm, at various time intervals, including 28 days post-treatment. Additionally, RGN-259 was also found to be safe and well-tolerated.

Prior to this, the company had reported preliminary safety and efficacy data from phase IIa exploratory study on RGN-259 for moderate dry eye syndrome. However, the study failed to meet a co-primary endpoint.

RegeneRx is planning on developing RGN-259 for several ophthalmic indications, including pursuing clinical development for the treatment of dry-eye syndrome and neurotrophic keratopathy (NK). RGN-259 enjoys orphan drug designation for the NK indication.

Some well-ranked stocks in the health care sector include Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Alexion Pharmaceuticals, Inc. ( ALXN ). While Gilead and Regeneron are Zacks Rank #1 (Strong Buy) stocks, Alexion holds a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: IND , ALXN , REGN , GILD , RGRX

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

66,728,054
  • $6.71 ▼ 4.82%
50,057,882
  • $3.405 ▼ 1.02%
35,473,755
  • $98.8099 ▲ 1.17%
34,318,094
  • $74.98 ▼ 0.28%
27,510,367
  • $15.50 ▼ 0.58%
26,213,765
  • $75.87 ▲ 25.07%
26,007,304
  • $56.13 ▲ 3.52%
24,178,669
  • $25.615 ▼ 0.68%
As of 7/28/2014, 02:23 PM